EUCTR2011-005336-25-DE进行中（未招募）不适用
A randomiszed, mono-center, placebo-controlled, double-blind, comparative study to evaluate the efficacy and safety of Dynexan® Mundgel in minors with acute painful sites of the mouth. - Dynexan® in children with acute painful sites of the mouth
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Male and female subjects, from 6 month to 8 years of age at the time of enrollment.
- •2.Written informed consent of the legal representative.
- •3.Verbal assent from minors = 4 years, written assent depending on intellectual maturity of the minor.
- •4.Ability to comply with the requirements of the study.
- •5.Clinical diagnosis of a painful site / s in the mouth (at least Face 2 = Hurts little more”) on the Wong-Baker FACES pain scale). The painful site have to be large enough to enable recognizing of pain reduction and may not be to large to for the amount of gel to be applied.
- •6.At least 2 of the following signs have to be reported by the legal representative at the screening examination: weeping, crying, grouching, mood swings, changes in behavior, and increase in body temperature above normal, sleepiness, or sick feeling. Small infants may appear over-sleepy or inactive, be irritable, vomit or feed poorly.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 222
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Participation in an investigational trial within 30 days prior to enrollment and for the whole study duration.
- •2.Any current uncontrolled infection.
- •3.Inflammatory oral and mucosal disease.
- •4.Known hypersensitivity to lidocaine or any of the ingredients of Dynexan® Mundgel (benzalkonium chloride, aromatic oil, galactomanan, glycerol, paraffin, saccharin sodium, silicon dioxide, thymol, titanium dioxide, vaseline).
- •5.Known pronounced allergic disposition.
- •6.Acute severe systemic disease or poor general health.
- •7.Severe generalized infection.
- •8.Acute strong febrile states.
- •9.Subjects with earache, or other painful situations.
- •10.Teething subjects with cleft palate.
- •11.Subjects with known history of instable diseases (diabetes, heart failures, etc.), consuming diseases (cancer), heritage diseases, or liver or renal insufficiency.
- •12.Any chronic or acute condition including the mucosa and skin, susceptible, in the opinion of the investigator, of interfering with the evaluation of the drug effect.
- •13.Subject with any of the following:·Known Ehlers-Danlos syndrome·Known Attention Deficit Hyperactivity (ADHD)
- •14.Systemic intake of pain relievers within 8 hours prior to enrollment and for the whole study duration.
- •15.Any local acting (mouth cavity) medication, including over the counter products and dietary supplements such as iodine, fluoride, or vitamins, which would interfere with study results, within 8 hours before and during the study course.
- •16.Subjects who are placed in an institution due to a judicial or official directive.
研究者
相似试验
招募中
2 期
OP-724-002 studyDecompensated cirrhosis related with HCV, HBV or NASHDecompensated cirrhosis, HCV, HBV, NASHD008103JPRN-jRCT2031230195Haruyama Yuushi93
进行中（未招募）
1 期
A clinical study investigating Myramistin versus Placebo for acute pharyngitisAcute PharyngitisEUCTR2018-002543-28-DEMEGAINPHARM GmbH220
进行中（未招募）
1 期
A clinical study investigating Myramistin versus Placebo for acute pharyngitisAcute PharyngitisEUCTR2018-002543-28-ATMEGAINPHARM GmbH220
进行中（未招募）
1 期
A multi-centre, randomized, placebo-controlled, double-blind trial to assess the efficacy and safety of nitroglycerin sublingual powder on walking distance in a scheduled forced titration design in patients with peripheral arterial occlusive disease (PAOD) and intermittent claudication.Peripheral arterial occlusive disease (PAOD, femoro-popliteal stenosis) and intermittent claudication (Fontaine stage IIb, pain-free walking distance < 200 m), lasting for at least 3 months to ensure clinical stabilityMedDRA version: 20.0 Level: LLT Classification code 10074576 Term: Peripheral arterial occlusive disease Fontaine stage IIb System Organ Class: 100000004866EUCTR2016-004460-19-DEG. Pohl-Boskamp GmbH & Co.KG100
进行中（未招募）
1 期
A multi-centre, randomized, placebo-controlled, double-blind, parallel-group study investigating safety and efficacy of a sore throat lozenge in the symptomatic treatment of patients with acute pharyngitis.Acute PharyngitisEUCTR2016-003962-24-DEMedice Arzneimittel Pütter GmbH & Co. KG320